4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background The role of catheter ablation in patients with symptomatic atrial fibrillation and
end-stage heart failure is unknown. Methods We conducted a single-center, open-label trial …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …